Alpine Immune Sciences, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mitchell H. Gold
- Full Time Employees
- 142
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 188 East Blaine Street Seattle WA United States of America 98102
- IPO Date
- Jun 17, 2015
- CIK
- 0001626199
- Website
- alpineimmunesciences.com
- Similar Companies
- Business
- Alpine Immune Sciences, Inc. (ALPN) develops protein-based immunotherapies for autoimmune and inflammatory diseases using proprietary protein engineering platforms, including directed evolution of immune proteins such as DIRA (Directed Inhibition of Receptors at the plasma membrane) and secreted immunomodulatory proteins. The company offers a pipeline featuring povetacicept (ALPN-303), a dual APRIL/BAFF inhibitor in Phase 3 for IgA nephropathy and other glomerulonephritides as well as Phase 2 for systemic lupus erythematosus and autoimmune cytopenias; acazicolcept (ALPN-104), a CD28 x ICOS antagonist in Phase 2 for systemic lupus erythematosus; and preclinical candidates such as SPEAR T-cell therapies in collaboration with Adaptimmune and discovery-stage programs N-1785 and N-1861 targeting cystic fibrosis. Alpine Immune Sciences, founded in 2015 and headquartered in Seattle, Washington, conducts operations primarily in the United States with strategic partnerships including expanded manufacturing collaboration with Evotec Biologics. In April 2024, Vertex Pharmaceuticals agreed to acquire Alpine Immune Sciences for $4.9 billion at $65 per share in cash, a transaction unanimously approved by both boards and expected to close in 2024 subject to regulatory approval, enhancing Vertex's immunology portfolio with povetacicept as a potential best-in-class treatment for renal autoimmune diseases.
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Could This Stock Be the Next Biotech Buyout?
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
2 Biotech Stocks Driving the Nasdaq Today
Vertex Pharmaceuticals to Buy Alpine Immune in $4.9B Deal
Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
Alpine Immune Sciences soars on $4.9bn Vertex takeover
Alpine Immune Sciences soars on $4.9bn Vertex takeover
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch
Shareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertex
Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal
ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders